|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-4.65/0.19
|
企業價值
141.46M
|
資產負債 |
每股賬面淨值
1.41
|
現金流量 |
現金流量率
0.39
|
損益表 |
收益
152.07M
|
每股收益
1.77
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/05/20 15:29 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain. |